Enzetron-Solofarm, 250 mg/ml 4 ml 5 pcs

Notropic agent. Citicoline, being a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: it promotes restoration of damaged cell membranes, inhibits phospholipases action, preventing excessive formation of free radicals and also prevents cell death by influencing apoptosis mechanisms.

In the acute period of stroke it reduces the volume of damaged tissue, improves cholinergic transmission.

In brain injury it reduces the duration of post-traumatic coma and the severity of neurological symptoms.

Cyticolin improves symptoms observed in hypoxia: impaired memory, emotional lability, lack of initiative, difficulty in performing daily activities and self-care.

It is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

Indications

Ischemic stroke (acute period); ischemic and hemorrhagic stroke (recovery period); traumatic brain injury (acute and recovery period); cognitive impairment in degenerative and vascular diseases of the brain.

Pharmacological effect

Nootropic drug. Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis.

In the acute period of stroke, it reduces the volume of damaged tissue and improves cholinergic transmission.

In case of traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms.

Citicoline improves the symptoms observed during hypoxia: memory impairment, emotional lability, lack of initiative, difficulties in performing daily activities and self-care.

Effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

Special instructions

Citicoline should not be used concomitantly with medicinal products containing meclofenoxate.

Active ingredient

Citicoline

Composition

The solution for oral administration is colorless, yellowish or yellowish-brown, transparent.

1 ml
citicoline sodium
104.5 mg,
which corresponds to the content of citicoline
100 mg

Excipients:

sorbitol liquid non-crystallizing – 200 mg,

glycerol anhydrous – 50 mg,

sodium citrate (sodium citrate dihydrate) – 6 mg,

anhydrous citric acid – up to pH 5.0-7.0,

water for up to 1 ml.

Contraindications

Vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system); children and adolescents up to 18 years of age; hypersensitivity to citicoline.

Side Effects

From the central nervous system and peripheral nervous system: insomnia, headache, dizziness, agitation, tremor, numbness in paralyzed limbs.

From the digestive system: nausea, loss of appetite, changes in the activity of liver enzymes.

Allergic reactions: rash, itchy skin, anaphylactic shock.

Other: fever; in some cases – short-term hypotensive effect, stimulation of the parasympathetic nervous system.

Interaction

Citicoline enhances the effects of L-dihydroxyphenylalanine.

Recommendations for use

When taken orally – 200-300 mg 3 times a day.

IV for strokes and traumatic brain injury in the acute period – 1-2 g/day, depending on the severity of the disease, for 3-7 days, followed by switching to IM administration or oral administration.

V/m – 0.5-1 g/day.

Functional features

Since citicoline is a naturally occurring compound found in the body, a classical pharmacokinetic study cannot be performed due to the difficulty of quantifying exogenous and endogenous citicoline.

Manufacturer

Grotex LLC, Russia